Promising finding: Diabetes drugs like ozempic show potential to reduce risk of malignant growth
Energizing new research emerged this week suggesting that a group of diabetes prescriptions, including the famous drug Ozempic, may be associated with a reduced risk of promoting specific malignant growths. This is a huge finding that offers a potential one-two punch for individuals with type 2 diabetes, helping them deal with glucose while possibly reducing the risk of malignant growth.
Grasping the connection: Corpulence and malignant growth
It is well established that an excessive muscle to fat ratio is a significant risk factor for several diseases. The American Society for Malignant Growth estimates that generally 40% of all analyzed tumors in the US are related to corpulence. The connection is complicated, however factors such as ongoing irritation and the hormonal discomfort caused by excess weight are accepted to contribute.
GLP-1 drugs and new research
The review, distributed in the renowned Diary of the American Clinical Affiliation (JAMA), focused on a class of drugs known as GLP-1 receptor agonists, or GLP-1 for short. Ozempic (semaglutide) is a notable illustration of a GLP-1 drug. These drugs work by mimicking a characteristic stomach chemical called glucagon-like peptide-1, which controls glucose levels.
Specialists in collaboration with Case Western Hold College conducted the revision examination. That is, they looked back at the existing clinical records of more than 1.6 million patients with type 2 diabetes treated somewhere between 2005 and 2018. They thought about the frequency of different tumors in patients who supported GLP-1 drugs versus those who did not. were treated with insulin alone.
Promising results: Reduced chance of specific tumors
The findings were empowering. People with type 2 diabetes who were prescribed GLP-1 showed a substantially lower chance of developing 10 of 13 severity-related tumors compared to those who were solely on insulin. The main decrease was seen in malignant growth of the large intestine, with GLP-1 clients showing almost half the risk. Various tumors showing the expected relationship with reduced risk included stomach-related tumors such as esophageal, gallbladder, and pancreatic malignancies.
Click here to read complete article.